/CNW/ - Today, AstraZeneca and Amgen announced the Canadian availability of Tezspire™ (tezepelumab injection), indicated for the add-on maintenance treatment.
[322 Pages Report] According to a recent study done by Future Market Insights, the oxygen therapy equipment market is expected to reach US$ 6.4 Billion by 2032, up from US$ Oxygen Therapy Equipment Market billion in 2022, expanding at a high CAGR of 7.4%. This study explains that the Chronic respiratory diseases aff.
Tezspire approved in Japan for the treatment of severe asthma astrazeneca.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from astrazeneca.com Daily Mail and Mail on Sunday newspapers.
New findings from the XALOC programme support the real-world effectiveness of Fasenra (benralizumab) in the management of patients with severe eosinophilic asthma (SEA), showing reductions in annualised asthma exacerbation rate (AAER), improvements in asthma control and the ability to achieve clinical remission .
AstraZeneca’s Tezspire (tezepelumab) has been recommended for marketing authorisation in the European Union (EU) as an add-on therapy in patients 12 years and older with severe asthma who are inadequately controlled with high dose inhaled corticosteroids plus another medicinal product for maintenance treatment. The .